Undisclosed MutSβ inhibitor therapeutic / LoQus23 - LARVOL DELTA

LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease (PRNewswire) - "LoQus23 Therapeutics Ltd...today announces the successful close of its £35 million (c.$43 million) Series A financing...The proceeds of the Series A financing will be primarily used to support the pre-clinical development and initial clinical studies of LoQus23's lead programme, an allosteric small molecule MutSβ inhibitor. The Company is preparing its lead programme to enter the clinic in 2026."

Financing • New trial • CNS Disorders • Huntington's Disease